comparemela.com

Latest Breaking News On - Australian stock exchange ath ax - Page 2 : comparemela.com

Alterity Therapeutics Announces Presentation of Novel

MELBOURNE, Australia and SAN FRANCISCO, Nov. 27, 2023 (GLOBE NEWSWIRE) Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a.

United statesSan franciscoRemy bernardaDavid stamlerPaula trujillo diazDaniel claassenHannah howlettInternational symposiumResearch assistant professorAlterity therapeuticsVanderbilt university medical centerCompany biomarkersEuropean commissionDepartment of neurologyMultiple system atrophyNatural history study

Alterity Therapeutics Completes Enrolment in ATH434-201

– ATH434-201 is a randomized, double-blind, placebo-controlled study in early-stage MSA – – Lead clinical development program enrolled 77 participants.

New zealandUnited statesSan franciscoHannah howlettDavid stamlerRemy bernardaEuropean commissionAlterity therapeuticsChief executive officerMultiple system atrophySystem atrophyMultiple systemMedia contactsSecurities actAustralian stock exchange ath axAlterity therapeutics limited

Appendix 4C – Q4 FY23 Quarterly Cash Flow Report

Highlights: ATH434-201 Phase 2 study on track to complete enrollment in Q3 2023 with top-line data expected by the end of 2024 in individuals with.

New zealandSan franciscoUnited statesUnited kingdomDavid stamlerHannah howlettRemy bernardaAlterity therapeuticsAmerican academy of neurology annual meetingSecurities exchangeAlterity therapeutics limitedData monitoring committeeMultiple system atrophyMonitoring committeeHistory studyTherapeutics limited

Alterity Therapeutics Enrolls First Patient in Australia in

MELBOURNE, Australia and SAN FRANCISCO, May 10, 2023 (GLOBE NEWSWIRE) Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a.

New south walesUnited statesSan franciscoDavid stamlerRemy bernardaStephen tischHannah howlettAlterity therapeuticsCompany phaseEuropean commissionMultiple system atrophyChief executive officerPrincipal investigatorSystem atrophyMedia contactsSecurities act

Appendix 4C – Q3 FY23 Quarterly Cash Flow Report

Highlights: Continued expansion of ATH434 Phase 2 Clinical Trial with sites open for recruitment in five countriesParticipants in the US and Europe.

United statesSan franciscoVanderbilt universityDavid stamlerInvestorand mediacontactsHannah howlettRemy bernardaAlterity therapeuticsVanderbilt university medical centerSecurities exchangeSachs associatesNeuroscience innovative forumAlterity therapeutics limitedAnnual neuroscience innovativeTherapeutics limitedQuarterly cash flow report

vimarsana © 2020. All Rights Reserved.